Evaluation of an α synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson disease

References

• Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson disease. Brain 1999; 122 ( Pt 8):1437-48; PMID:10430830; http://dx.doi.org/10.1093/brain/122.8.1437
   PubMed Web of Science ®Google Scholar
• Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973; 20:415-55; PMID:4272516; http://dx.doi.org/10.1016/0022-510X(73)90175-5
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 1998; 95:6469-73; PMID:9600990; http://dx.doi.org/10.1073/pnas.95.11.6469
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson disease (preclinical and clinical stages). J Neurol 2002; 249 Suppl 3):III/1-5; PMID:11954855; http://dx.doi.org/10.1007/s00415-002-1301-4
   PubMedGoogle Scholar
• Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009; 119:182-92; PMID:19104149
   PubMed Web of Science ®Google Scholar
• Berardelli A, Rothwell JC, Thompson PD, Hallett M. Pathophysiology of bradykinesia in Parkinson disease. Brain 2001; 124:2131-46; PMID:11673316; http://dx.doi.org/10.1093/brain/124.11.2131
   PubMed Web of Science ®Google Scholar
• Tran HT, Chung CH, Iba M, Zhang B, Trojanowski JQ, Luk KC, Lee VM. Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration. Cell Rep 2014; 7:2054-65; PMID:24931606; http://dx.doi.org/10.1016/j.celrep.2014.05.033
   PubMed Web of Science ®Google Scholar
• Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, et al. Passive immunization reduces behavioral and neuropathological deficits in an α-synuclein transgenic model of Lewy body disease. PloS One 2011; 6:e19338; PMID:21559417; http://dx.doi.org/10.1371/journal.pone.0019338
   PubMed Web of Science ®Google Scholar
• Games D, Valera E, Spencer B, Rockenstein E, Mante M, Adame A, Patrick C, Ubhi K, Nuber S, Sacayon P, et al. Reducing C-terminal-truncated α-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson disease-like models. J Neurosci 2014; 34:9441-54; PMID:25009275; http://dx.doi.org/10.1523/JNEUROSCI.5314-13.2014
   PubMed Web of Science ®Google Scholar
• Schneeberger A, Mandler M, Mattner F, Schmidt W. Vaccination for Parkinson disease. Parkinsonism Relat Disord 2012; 18 Suppl 1:S11-3; PMID:22166404; http://dx.doi.org/10.1016/S1353-8020(11)70006-2
   PubMed Web of Science ®Google Scholar
• Sanchez-Guajardo V, Annibali A, Jensen PH, Romero-Ramos M. α-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model. J Neuropathol Exp Neurol 2013; 72:624-45; PMID:23771222; http://dx.doi.org/10.1097/NEN.0b013e31829768d2
   PubMed Web of Science ®Google Scholar
• Mougenot AL, Betemps D, Hogeveen KN, Kovacs GG, Chouaf-Lakhdar L, Milhavet O, Lehmann S, Legastelois S, Pin JJ, Baron TG. Production of a monoclonal antibody, against human α-synuclein, in a subpopulation of C57BL/6J mice, presenting a deletion of the α-synuclein locus. J Neurosci Methods 2010; 192:268-76; PMID:20709102; http://dx.doi.org/10.1016/j.jneumeth.2010.08.010
   PubMed Web of Science ®Google Scholar
• Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, et al. Effects of α-synuclein immunization in a mouse model of Parkinson disease. Neuron 2005; 46:857-68; PMID:15953415; http://dx.doi.org/10.1016/j.neuron.2005.05.010
   PubMed Web of Science ®Google Scholar
• Hirsch E, Ruberg M, Dardenne M, Portier MM, Javoy-Agid F, Bach JF, Agid Y. Monoclonal antibodies raised against Lewy bodies in brains from subjects with Parkinson disease. Brain Res 1985; 345:374-8; PMID:2994847; http://dx.doi.org/10.1016/0006-8993(85)91020-0
   PubMedGoogle Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52; PMID:9521319; http://dx.doi.org/10.1038/32588
   PubMed Web of Science ®Google Scholar
• Steinman RM. The dendritic cell system and its role in immunogenicity. Annual Rev Immunol 1991; 9:271-96; PMID:1910679; http://dx.doi.org/10.1146/annurev.iy.09.040191.001415
   PubMed Web of Science ®Google Scholar
• Dubois B, Bridon JM, Fayette J, Barthelemy C, Banchereau J, Caux C, Briere F. Dendritic cells directly modulate B cell growth and differentiation. J Leukoc Biol 1999; 66:224-30; PMID:10449158
   PubMed Web of Science ®Google Scholar
• Dubois B, Vanbervliet B, Fayette J, Massacrier C, Van Kooten C, Briere F, Banchereau J, Caux C. Dendritic cells enhance growth and differentiation of CD40-activated B lymphocytes. J Exp Med 1997; 185:941-51; PMID:9120400; http://dx.doi.org/10.1084/jem.185.5.941
   PubMed Web of Science ®Google Scholar
• Fayette J, Dubois B, Vandenabeele S, Bridon JM, Vanbervliet B, Durand I, Banchereau J, Caux C, Briere F. Human dendritic cells skew isotype switching of CD40-activated naive B cells towards IgA1 and IgA2. J Exp Med 1997; 185:1909-18; PMID:9166420; http://dx.doi.org/10.1084/jem.185.11.1909
   PubMed Web of Science ®Google Scholar
• Clark EA. Regulation of B lymphocytes by dendritic cells. J Exp Med 1997; 185:801-3; PMID:9120385; http://dx.doi.org/10.1084/jem.185.5.801
   PubMedGoogle Scholar
• Barrou B, Benoit G, Ouldkaci M, Cussenot O, Salcedo M, Agrawal S, Massicard S, Bercovici N, Ericson ML, Thiounn N. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol Immunother 2004; 53:453-60; PMID:14760510; http://dx.doi.org/10.1007/s00262-003-0451-2
   PubMed Web of Science ®Google Scholar
• Cohen S, Haimovich J, Hollander N. B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice. J Immunother 2005; 28:461-6; PMID:16113602; http://dx.doi.org/10.1097/01.cji.0000171312.16171.77
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Fallarino F, Ashikari A, Sherman M. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res 2001; 7:895s-901s; PMID:11300489
   PubMed Web of Science ®Google Scholar
• Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, Pietersz GA, Apostolopoulos V, Vaughan H, Karanikas V, et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 2006; 12:869-77; PMID:16467101; http://dx.doi.org/10.1158/1078-0432.CCR-05-1574
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Storrer CE, Foley RJ, Harris K, Jama Y, Shriver CD, Ponniah S, Peoples GE. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer 2006; 106:2309-17; PMID:16596621; http://dx.doi.org/10.1002/cncr.21849
   PubMed Web of Science ®Google Scholar
• Satthaporn S, Eremin O. Dendritic cells (II): Role and therapeutic implications in cancer. J R Coll Surg Edinb 2001; 46:159-67; PMID:11478013
   PubMedGoogle Scholar
• Ide F, Nakamura T, Tomizawa M, Kawana-Tachikawa A, Odawara T, Hosoya N, Iwamoto A. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial. J Med Virol 2006; 78:711-8; PMID:16628588; http://dx.doi.org/10.1002/jmv.20612
   PubMed Web of Science ®Google Scholar
• Pellegatta S, Poliani PL, Corno D, Grisoli M, Cusimano M, Ubiali F, Baggi F, Bruzzone MG, Finocchiaro G. Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice. Neurol Res 2006; 28:527-31; PMID:16808884; http://dx.doi.org/10.1179/016164106X116809
   PubMed Web of Science ®Google Scholar
• Cao C, Lin X, Zhang C, Wahi MM, Wefes I, Arendash G, Potter H. Mutant amyloid-β-sensitized dendritic cells as Alzheimer disease vaccine. J Neuroimmunol 2008; 200:1-10; PMID:18649951; http://dx.doi.org/10.1016/j.jneuroim.2008.05.017
   PubMedGoogle Scholar
• Luo Z, Li J, Nabar NR, Lin X, Bai G, Cai J, Zhou SF, Cao C, Wang J. Efficacy of a therapeutic vaccine using mutated β-amyloid sensitized dendritic. J Neuroimmune Pharmacol 2012; 7:640-55; PMID:22684353; http://dx.doi.org/10.1007/s11481-012-9371-2
   PubMedGoogle Scholar
• Nabar NR, Yuan F, Lin X, Wang L, Bai G, Mayl J, Li Y, Zhou SF, Wang J, Cai J, et al. Cell therapy: a safe and efficacious therapeutic treatment for Alzheimer disease in APP+PS1 mice. PloS One 2012; 7:e49468; PMID:23226497; http://dx.doi.org/10.1371/journal.pone.0049468
   PubMedGoogle Scholar
• Wesley JD, Whitmore J, Trager J, Sheikh N. An overview of sipuleucel-T: autologous cellular immunotherapy for prostate cancer. Hum Vaccin Immunother 2012; 8:520-7; PMID:22370520; http://dx.doi.org/10.4161/hv.18769
   PubMed Web of Science ®Google Scholar
• Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18:3894-903; PMID:11099318
   PubMed Web of Science ®Google Scholar
• Sims RB. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer. Vaccine 2012; 30:4394-7; PMID:22122856; http://dx.doi.org/10.1016/j.vaccine.2011.11.058
   PubMed Web of Science ®Google Scholar
• Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997; 90:3245-87; PMID:9345009
   PubMed Web of Science ®Google Scholar
• Steinman RM. Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation. Mt Sinai J Med 2001; 68:160-6; PMID:11373688
   PubMed Web of Science ®Google Scholar
• Shaftel SS, Griffin WS, O'Banion MK. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation 2008; 5:7; PMID:18302763; http://dx.doi.org/10.1186/1742-2094-5-7
   PubMed Web of Science ®Google Scholar
• Hirsch EC, Hunot S. Neuroinflammation in Parkinson disease: a target for neuroprotection? Lancet Neurol 2009; 8:382-97; PMID:19296921; http://dx.doi.org/10.1016/S1474-4422(09)70062-6
   PubMed Web of Science ®Google Scholar
• Basu A, Krady JK, Levison SW. Interleukin-1: a master regulator of neuroinflammation. J Neurosci Res 2004; 78:151-6; PMID:15378607; http://dx.doi.org/10.1002/jnr.20266
   PubMed Web of Science ®Google Scholar
• Fernagut P-O, Chesselet M-F. Alpha-synuclein and transgenic mouse models. Neurobiol Dis 2004; 17:123-30; PMID:15474350; http://dx.doi.org/10.1016/j.nbd.2004.07.001
   PubMedGoogle Scholar
• Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, et al. A[β] peptide vaccination prevents memory loss in an animal model of Alzheimer disease. Nature, 2000; 408:982-5; PMID:11140686
   PubMed Web of Science ®Google Scholar
• McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, French JE, Lambermon MH, Darabie AA, Brown ME; et al. Therapeutically effective antibodies against amyloid-[β] peptide target amyloid-[β] residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 2002; 8:1263-9.
   PubMed Web of Science ®Google Scholar
• Vasilevko V, Head E. Immunotherapy in a natural model of Abeta pathogenesis: the aging beagle. CNS Neurol Disord Drug Targets 2009; 8:98-113; PMID:19355931; http://dx.doi.org/10.2174/187152709787847333
   PubMedGoogle Scholar
• Cicin-Sain L, Smyk-Pearson S, Currier N, Byrd L, Koudelka C, Robinson T, Swarbrick G, Tackitt S, Legasse A, Fischer M, et al. Loss of naive T cells and repertoire constriction predict poor response to vaccination in old primates. J Immunol 2010; 184:6739-45; http://dx.doi.org/10.4049/jimmunol.0904193
   PubMed Web of Science ®Google Scholar
• Sela M, Arnon R, Schechter B. Therapeutic vaccines: realities of today and hopes for the future. Drug Discov Today 2002; 7:664-73; PMID:12110243; http://dx.doi.org/10.1016/S1359-6446(02)02296-1
   PubMed Web of Science ®Google Scholar
• Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, et al. Effects of α-synuclein immunization in a mouse model of Parkinson disease. Neuron 2005; 46:857-68; PMID:15953415; http://dx.doi.org/10.1016/j.neuron.2005.05.010
   PubMed Web of Science ®Google Scholar
• Bachy V, Ballerini C, Gourdain P, Prignon A, Iken S, Antoine N, Rosset M, Carnaud C. Mouse vaccination with dendritic cells loaded with prion protein peptides overcomes tolerance and delays scrapie. J Gen Virol 2010; 91:809-20; PMID:19864503; http://dx.doi.org/10.1099/vir.0.013417-0
   PubMedGoogle Scholar
• Okano F, Merad M, Furumoto K, Engleman EG. In vivo manipulation of dendritic cells overcomes tolerance to unmodified tumor-associated self antigens and induces potent antitumor immunity. J Immunol 2005; 174:2645-52; http://dx.doi.org/10.4049/jimmunol.174.5.2645
   PubMed Web of Science ®Google Scholar
• Farag MM, Tedjokusumo R, Flechtenmacher C, Asen T, Stremmel W, Muller M, Protzer U, Weigand K. Immune tolerance against HBV can be overcome in HBV transgenic mice by immunization with dendritic cells pulsed by HBVsvp. Vaccine 2012; 30:6034-9; PMID:22867720; http://dx.doi.org/10.1016/j.vaccine.2012.07.057
   PubMed Web of Science ®Google Scholar
• Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, et al. A β peptide vaccination prevents memory loss in an animal model of Alzheimer disease. Nature 2000; 408:982-5; PMID:11140686; http://dx.doi.org/10.1038/35050116
   PubMed Web of Science ®Google Scholar
• Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004; 64:4973-9; PMID:15256471; http://dx.doi.org/10.1158/0008-5472.CAN-03-3505
   PubMed Web of Science ®Google Scholar
• Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, Vieweg J, Gilboa E. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000; 6:1011-7; PMID:10973321; http://dx.doi.org/10.1038/79519
   PubMed Web of Science ®Google Scholar
• Gruber A, Chalmers AS, Rasmussen RA, Ong H, Popov S, Andersen J, Hu SL, Ruprecht RM. Dendritic cell-based vaccine strategy against human immunodeficiency virus clade C: skewing the immune response toward a helper T cell type 2 profile. Viral Immunol 2007; 20:160-9; PMID:17425430; http://dx.doi.org/10.1089/vim.2006.0052
   PubMedGoogle Scholar
• Boscardin SB, Hafalla JC, Masilamani RF, Kamphorst AO, Zebroski HA, Rai U, Morrot A, Zavala F, Steinman RM, Nussenzweig RS, et al. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med 2006; 203:599-606; PMID:16505139; http://dx.doi.org/10.1084/jem.20051639
   PubMed Web of Science ®Google Scholar
• Nabar NR, Yuan F, Lin X, Wang L, Bai G, Mayl J, Li Y, Zhou SF, Wang J, Cai J, et al. Cell therapy: a safe and efficacious therapeutic treatment for Alzheimer disease in APP+PS1 mice. PLoS One, 2012;7:e49468; http://dx.doi.org/10.1371/journal.pone.0049468
   Google Scholar
• Luo Z, Li J, Nabar NR, Lin X, Bai G, Cai J, Zhou SF, Cao C, Wang J. Efficacy of a therapeutic vaccine using mutated β-amyloid sensitized dendritic cells in Alzheimer mice. J Neuroimmune Pharmacol 2012; 7:640-55; PMID:22684353; http://dx.doi.org/10.1007/s11481-012-9371-2
   PubMedGoogle Scholar
• Ikeda S, Saijo S, Murayama MA, Shimizu K, Akitsu A, Iwakura Y. Excess IL-1 signaling enhances the development of Th17 cells by downregulating TGF-β-induced Foxp3 expression. J Immunol 2014; 192:1449-58; http://dx.doi.org/10.4049/jimmunol.1300387
   PubMed Web of Science ®Google Scholar
• Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 2014; 13:668-77; PMID:24418308; http://dx.doi.org/10.1016/j.autrev.2013.12.004
   PubMed Web of Science ®Google Scholar
• Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron 2002; 34:521-33; PMID:12062037; http://dx.doi.org/10.1016/S0896-6273(02)00682-7
   PubMed Web of Science ®Google Scholar
• Cao C, Lin X, Zhang C, Wahi M, Wefes I, Arendash G, Potter H. Mutant amyloid-β-sensitized dendritic cells as Alzheimer disease vaccine. J Neuroimmunol 2008; 200:1-10; PMID:18649951; http://dx.doi.org/10.1016/j.jneuroim.2008.05.017
   PubMedGoogle Scholar
• Rozas G, Guerra MJ, Labandeira-Garcia JL. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res Brain Res Protoc 1997; 2:75-84; PMID:9438075; http://dx.doi.org/10.1016/S1385-299X(97)00034-2
   PubMedGoogle Scholar
• Meredith GE, Kang UJ. Behavioral models of Parkinson disease in rodents: a new look at an old problem. Mov Disord 2006; 21:1595-606; PMID:16830310; http://dx.doi.org/10.1002/mds.21010
   PubMedGoogle Scholar
• Cao C, Lin X, Wahi MM, Jackson EA, Potter H, Jr. Successful adjuvant-free vaccination of BALB/c mice with mutated amyloid β peptides. BMC Neurosci. England, 2008; 9:25.
   Google Scholar